Strategic Buy Lights Up This Biotech Stock: Time to Invest? 10x Genomics (NASDAQ:TXG) reported a first-quarter revenue increase excluding prior-year settlement revenue and used its earnings call to ...

Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the first quarter ended March 31, 2026.

Shares of biotech company 10x Genomics (NASDAQ:TXG) fell 5.3% in the afternoon session after its first-quarter results, although beating expectations, were overshadowed by concerns about its future ...

Genomics provides advanced tools for single cell and spatial biology research, serving academic and biopharma institutions worldwide.

Forbes contributors publish independent expert analyses and insights. Steven covers accessibility and assistive technologies. Aug 07, 2023, 01:54pm EDT Aug 07, 2023, 03:58pm EDT This article is more ...

10x Genomics has launched its initial public offering (IPO), raising an estimated $357.5 million in net proceeds, then seeing its share price climb up to 48% in first-day trading. The IPO comes a day ...

PLEASANTON — 10x Genomics has marked a new phase in its remarkable expansion by opening a modern office building that has just sprouted in Pleasanton, coupled with plans for even more growth at its ...

The latest price target for 10x Genomics (NASDAQ:TXG) was reported by Morgan Stanley on May 12, 2026. The analyst firm set a price target for $22.00 expecting TXG to fall to within 12 months (a ...

Collaboration will engage leading transplant clinician-scientists to study antibody-mediated rejection (AMR) and microvascular inflammation (MVI) using cellular-resolution profiling BRISBANE, Calif.-- ...

PLEASANTON, Calif., May 7, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for ...